Blog
RSS FeedPosted by Michael Wonder on 24 Mar 2017
Cost effective but unaffordable: an emerging challenge for health systems
23 March 2017 - New “budget impact test” is an unpopular and flawed attempt to solve a fundamentally political problem ...
Posted by Michael Wonder on 06 Feb 2017
Medicines evaluation not keeping pace with scientific progress, says ABPI
3 February 2017 - Following the news that a new breast cancer medicine - palbociclib - from Pfizer has been ...
Posted by Michael Wonder on 01 Feb 2017
Institute for Clinical and Economic Review posts revised value assessment framework for public comment
1 February 2017 - Dr. Steven Pearson, ICER's President, will present proposed changes during 13 February webinar. ...
Posted by Michael Wonder on 21 Jan 2017
New health technologies: managing access, value and sustainability
16 January 2017 - This report discusses the need for an integrated and cyclical approach to managing health technology in order ...
Posted by Michael Wonder on 19 Jan 2017
Drug cost-saving plans may hit patients
19 January 2017 - Patients in England may face delays getting new drugs or go without them if NHS bosses ...
Posted by Michael Wonder on 19 Jan 2017
Cost-effectiveness analysis 2.0
18 January 2017 - As prominent groups in U.S. health care ramp up use of cost-effectiveness analysis to measure and communicate ...
Posted by Michael Wonder on 30 Dec 2016
Assessment of overall survival, quality of life, and safety benefits associated with new cancer medicines
29 December 2016 - What are the overall survival, quality of life, and safety benefits of recently licensed cancer medicines? ...
Posted by Michael Wonder on 29 Dec 2016
Should Medicare value based purchasing take social risk into account?
28 December 2016 - The United States is rapidly moving to a health care delivery system in which value-based payment ...
Posted by Michael Wonder on 12 Dec 2016
Pay-for-performance drug pricing: drug makers asked to eat costs when products don't deliver
10 December 2016 - The latest wrinkle in the fight against rising drug prices involves insurers and pharmacy benefit managers ...
Posted by Michael Wonder on 09 Dec 2016
When the price is right: drug costing and NICE approval
5 December 2016 - Price discounts are leading to a flurry of NICE approvals. ...
Posted by Michael Wonder on 22 Nov 2016
High prices for some leukaemia drugs will make them less cost-effective
21 November 2016 - Pills used to treat a form of leukaemia may be more effective and convenient than chemotherapy, ...
Posted by Michael Wonder on 19 Nov 2016
The value of medicines: a crucial but vague concept
20 November 2016 - Health technology assessment is increasingly used to evaluate the value of health care products and to prioritise ...
Posted by Michael Wonder on 16 Nov 2016
AMA embraces value-based drug pricing
15 November 2016 - The US' largest physician organisation is supporting value-based pricing for medications. ...
Posted by Michael Wonder on 02 Nov 2016
New expensive anti-cancer agents: which role is played by quality-adjusted life-years in the selection of a specific treatment?
1 November 2016 - Koczwara et al. emphasise that dissemination and implementation science should broaden its reach beyond its current geographic ...
Posted by Michael Wonder on 20 Oct 2016
Oncologists knock ICER's lung cancer cost-effectiveness review
20 October 2016 - Ahead of an ICER meeting to review evidence and vote on cost-effectiveness ratings for new medicines ...